The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Hermans, Michel P ^a   Ahn, Sylvie A ^a   Rousseau, Michel F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

cell function; Cardiovascular risk; Diabetes; Gender; HDL C; Hyperbolic product; Microangiopathy; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYSTATIN C; ENDOTHELIN 1; EZETIMIBE; FENOFIBRATE; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; URIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN RELEASE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MICROANGIOPATHY; MICROVASCULATURE; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; RISK ASSESSMENT; SEDENTARY LIFESTYLE; SELF REPORT; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; RISK FACTORS; TRIGLYCERIDES;

EID: 84867121921     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-132     Document Type: Article

References (45)

1. Standards of medical care in diabetes-2009. American Diabetes Association, Diabetes Care 2009 32 13 S61 19118286
2. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL, J Am Coll Cardiol 2008 51 1512 1524 10.1016/j.jacc.2008.02.034 18402913
3. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche J-M, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P for the Residual Risk Reduction Initiative, Am J Cardiol 2008 102 1 34 10.1016/j.amjcard.2008.02.089 18572027
4. Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here? Hermans MP, Fruchart JC, Clinical Lipidology 2010 5 811 826 10.2217/clp.10.65
5. Residual vascular risk in T2DM: the next frontier. Hermans MP, Ahn SA, Rousseau MF, Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications Rijeka (Croatia): Intech 2011
6. Triglycerides: a risk factor for coronary heart disease. Davignon J, Cohn JS, Atherosclerosis 1996 124 Suppl 57 S64 8831917
7. Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Hermans MP, Ahn SA, Rousseau MF, Cardiovasc Diabetol 2010 9 88 10.1186/1475-2840-9-88 21156040
8. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, Lancet 2010 375 1634 1639 20452521
9. Effects of combination lipid therapy in type 2 diabetes mellitus. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP, ACCORD Study Group, N Engl J Med 2010 362 1563 1574 20228404
10. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i). Fruchart J-C, Sacks FM, Hermans MP, Curr Med Res Opin 2010 26 1793 1797 10.1185/03007995.2010.489341 20482323
11. Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD. Hermans MP, Diab Vasc Dis Res 2011 8 180 189 10.1177/1479164111407783 21576195
12. Impact of gender on diabetes mellitus and its associated cardiovascular risk factors. Singh R, Wiegers SE, Goldstein BJ, J Gend Specif Med 2001 4 28 36 11605353
13. Evidence-based guidelines for cardiovascular disease prevention in women. Mosca L, Appel LJ, Benjamin EJ, American Heart Association, American College of Cardiology, American College of Nurse Practitioners, American College of Obstetricians and Gynecologists, American College of Physicians, American Medical Women's Association, Association of Black Cardiologists, Centers for Disease Control and Prevention, National Heart, Lung, and Blood Institute, National Institutes of Health, Office of Research on Women's Health, Society of Thoracic Surgeons and World Heart Federation, et al. J Am Coll Cardiol 2004 43 900 921 10.1016/j.jacc.2004.02.001 14998635
14. Writing Group for The Partnership for Gender-Specific Medicine. Gender-specific care of the patient with diabetes: review and recommendations. Legato MJ, Gelzer A, Goland R, Ebner SA, Rajan S, Villagra V, Kosowski M, Gend Med 2006 3 131 158 10.1016/S1550-8579(06)80202-0 16860272
15. Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. Hermans MP, Ahn S, Rousseau MF, Diabetes Metab Syndr Clin Res Rev 2008 2 93 98 10.1016/j.dsx.2008.02.001
16. UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR, Diabetes Care 2004 27 201 207 10.2337/diacare.27.1. 201 14693990
17. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, Circulation 2009 120 1640 1645 10.1161/CIRCULATIONAHA.109.192644 19805654
18. Here we go again. The metabolic syndrome revisited! Sadikot S, Hermans MP, Diab Metab Syndr 2010 4 111 120 10.1016/j.dsx.2010.05.011
19. A new index of abdominal adiposity as an indicator of risk for cardiovascular disease: a cross-population study. Valdez R, Seidell JC, Ahn YI, Weiss KM, Int J Obes 1992 16 77 82
20. Sedentarism affects body fat mass index and fat-free mass index in adults aged 18 to 98 years. Kyle UG, Morabia A, Schutz Y, Pichard C, Nutrition 2004 20 255 260 10.1016/j.nut.2003.11.019 14990265
21. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. Burkhauser RV, Cawley J, J Health Econ 2008 27 519 529 10.1016/j.jhealeco.2007.05.005 18166236
22. Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMA-hyperbolic product. Dehout F, Haumont S, Gaham N, Amoussou-Guenou KD, Hermans MP, Diab Metab Syndr 2008 2 5 11 10.1016/j.dsx.2007.11.008
23. Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Munoko T, Hermans MP, Diab Met Syndr 2008 2 115 124 10.1016/j.dsx.2008.02.004
24. Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea syndrome. Hermans MP, Ahn SA, Rousseau MF, Diabetes Metab Syndr 2009 3 50 54 10.1016/j.dsx.2008.10.011
25. Micro- and macrovascular risk and complications in T2DM males with obstructive sleep apnoea. Hermans MP, Ahn SA, Rousseau MF, J Clin Metab Diab 2011 2 64 70
26. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Levy JC, Matthews DR, Hermans MP, Diabetes Care 1998 21 2191 2192 10.2337/diacare.21.12.2191 9839117
27. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Hermans MP, Levy J, Morris RJ, Turner RC, Diabetologia 1999 42 678 687 10.1007/s001250051215 10382587
28. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Hermans MP, Levy J, Morris RJ, Turner RC, Diabetes 1999 48 1779 1786 10.2337/diabetes.48.9.1779 10480608
29. Diabetic macro- and microvascular disease in type 2 diabetes. Hermans MP, Diabetes Vasc Dis Res 2007 4 7 S11
30. Statin therapy and cataract in Type 2 diabetes. Hermans MP, Ahn SA, Rousseau MF, Diabetes Metab 2011 37 139 143 10.1016/j.diabet.2010.09.005 21145274
31. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10075613
32. The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. Hermans MP, Ahn SA, Gruson D, Rousseau MF, Diab Metab Syndr 2007 1 229 237 10.1016/j.dsx.2007.09.001
33. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein- depleted plasma (FERHDL). Dobiásová M, Frohlich J, Clin Biochem 2001 34 583 588 10.1016/S0009-9120(01)00263-6 11738396
34. The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: comparison with reference lipid markers. Hermans MP, Ahn SA, Rousseau MF, Diab Metab Syndr 2007 1 23 28 10.1016/j.dsx.2006.11.003
35. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC, Clinics (Sao Paulo) 2008 63 427 432
36. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ, Am J Cardiol 2008 101 497 501 10.1016/j.amjcard.2007.09.109 18312765
37. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, Bairey-Merz CN, Sopko G, Am Heart J 2009 157 548 555 10.1016/j.ahj.2008.11.014 19249427
38. Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Cordero A, Andrés E, Ordoñez B, León M, Laclaustra M, Grima A, Luengo E, Moreno J, Bes M, Pascual I, Civeira F, Pocoví M, Alegría E, Casasnovas JA, MESYAS (MEtabolic Syndrome Active Subjects) Study Investigators, Am J Cardiol 2009 104 1393 1397 10.1016/j.amjcard.2009.07.008 19892056
39. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M, Metabolism 2010 59 299 304 10.1016/j.metabol.2009.07.027 19796777
40. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Hermans MP, Sacks F, Ahn SA, Rousseau MF, Cardiovasc Diabetol 2011 10 20 10.1186/1475-2840-10-20 21356116
41. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR, Diabet Med 1998 15 290 296 10.1002/(SICI)1096-9136(199804)15:4<290::AID- DIA570>3.0.CO;2-M 9585393
42. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Turner RC, Cull CA, Frighi V, Holman RR, JAMA 1999 281 2005 2012 10.1001/jama.281.21.2005 10359389
43. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U, Circulation 2010 121 110 122 10.1161/CIRCULATIONAHA.108.836346 20026785
44. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM, Cardiovasc Diabetol 2008 7 4 10.1186/1475-2840-7-4 18307789
45. Reducing vascular events risk in patients with dyslipidemia: an update for clinicians. Hermans MP, Fruchart JC, Ther Adv Chronic Dis 2011 2 307 323 10.1177/2040622311413952